We recently compiled a list of 9 Most Undervalued Pharma Stocks to Buy Right Now. Teva Pharmaceuticals Industries Limited is one of the most undervalued stocks on our list. TheFly reported on December 9 that Bank of America Securities analyst Jason Gerberry reaffirmed a Buy rating on TEVA and raised his price target to $32.00, reflecting conviction that the stock remains undervalued relative to its improving revenue trajectory and debt reduction progress. Also on December 9, 2025, Barclays analyst Glen S ...

We recently compiled a list of 9 Most Undervalued Pharma Stocks to Buy Right Now. Sanofi is among the most undervalued stocks.  Between December 8 and December 10, 2025, SNY faced a series of analyst rating adjustments that tempered investor sentiment. The Fly reported on Monday, December 8, 2025, that J.P. Morgan downgraded SNY from Overweight to Neutral, signaling a more cautious near-term outlook for the company. The following day, Guggenheim lowered its rating from Buy to Neutral, marking a second do ...

Key Points One is a sector mainstay that has now raised its payout 17 years in a row. The other is a big player in the animal healthcare space. It's not too late to take advantage of either. 10 stocks we like better than Bristol Myers Squibb › While the pre-holiday season isn't usually a busy time for dividend raises, investors can usually expect a few companies to end the year on a high note by declaring one. Sure enough, in the fading weeks of 2025, we've seen a smattering of payout hikes. Tw ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Telix Pharmaceuticals Ltd. securities between February 21, 2025, and August 28, 2025, about the January 9, 2026, deadline to become a lead plaintiff in a securities class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Telix securities during the specified Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting the firm or visiting their website [3][6]. - The lawsuit alleges that Telix made materially false and misleading statements regarding its prostate cancer therapeutic candidates and the quality of its supply chain, leading to investor damages when the truth was revealed [5]. Group 2: Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in achieving significant settlements for investors [4]. - The firm has been recognized for its performance in securities class action settlements, including being ranked No. 1 by ISS Securities Class Action Services in 2017 and recovering over $438 million for investors in 2019 alone [4].

– End-of-Phase 2 interactions with FDA complete; scientific advice received from EMA – – Company expects to dose first patient in global Phase 3 registrational trial, MAPKeeper 301, in mid-2026 – – Overall survival update for Phase 2a trial of atebimetinib + mGnP in first-line pancreatic cancer patients planned in coming weeks – NEW YORK, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them ...

The U.S. Food and Drug Administration is moving to fast-track reviews of two experimental Merck drugs with multibillion-dollar potential, according to internal documents seen by Reuters. ...

Core Insights - The VanEck Pharmaceutical ETF (PPH) has demonstrated lower volatility compared to broader markets while maintaining competitive total returns, appealing to investors who prioritize earnings visibility and balance-sheet strength [1] Group 1 - The VanEck Pharmaceutical ETF (PPH) is positioned defensively, resulting in lower volatility than the overall market [1] - Despite its defensive nature, the ETF has not significantly lagged in total returns, indicating a balanced performance [1] - The ETF is attractive for investors focused on earnings visibility and strong balance sheets, suggesting a stable investment option in the pharmaceutical sector [1]

My last analysis of argenx SE ( ARGX ) followed an on-the-market safety event for its lead product, VYVGART HYTRULO (subcutaneous efgartigimod). The issue, however, seemed more related to how CIDP patients are transitioned from IVIG to VYVGART HYTRULO, rather than just the drug itself. AsAnalyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it exp ...

Core Insights - Investors are showing a bullish stance on AbbVie (NYSE:ABBV), indicating potential upcoming developments that may influence the stock price [1][2] - The options trading activity reveals a split sentiment among large investors, with 43% bullish and 43% bearish positions [3] Options Trading Activity - Benzinga's options scanner identified 16 uncommon options trades for AbbVie, with a total of $1,449,383 in call options and $97,520 in put options [2][3] - Major market movers are focusing on a price range between $120.0 and $250.0 for AbbVie over the last three months [4] - The volume and open interest data for AbbVie's options indicate significant liquidity and interest, particularly within the strike price range of $120.0 to $250.0 [5] Options Snapshot - Notable options trades include: - A bearish call sweep for a strike price of $220.00 with a total trade price of $293.4K [9] - A bullish call sweep for a strike price of $230.00 with a total trade price of $226.5K [9] - Additional bearish call sweeps for the same strike price of $220.00 with total trade prices of $190.9K and $183.3K [9] Company Overview - AbbVie is a pharmaceutical company with strong exposure in immunology and oncology, having expanded its portfolio through acquisitions, including Allergan in 2020 and recent acquisitions of Cerevel and ImmunoGen [10] - Current market consensus from analysts suggests a target price of $267.0 for AbbVie, with ratings from Morgan Stanley and HSBC indicating an Overweight and Buy rating, respectively [12][13] Current Market Performance - AbbVie’s stock price is currently at $225.83, reflecting a 0.97% increase with a trading volume of 2,394,007 [15] - The stock's current RSI values suggest a neutral position between overbought and oversold [15]

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...